A regulatory “green light” (Medicare PDAC) turns Cheelcare from an R&D story into a manufacturing-and-reimbursement execution race—with major upside if dealer activation and margin scaling land on time.
Overview
Cheelcare Inc. (CHER.V) is a Canadian medical technology company focused on complex rehabilitation technology and advanced mobility, integrating robotics with user-centric industrial design. It operates across the value chain—R&D through manufacturing and commercialization—targeting a large global population with mobility impairment. The business is diversified across (1) Companion, a front-mounted power add-on that converts manual wheelchairs into motorized mobility; (2) Curio, a high-end robotic wheelchair for complex rehab with patented omni-directional movement and auto-leveling; (3) AWARE accessories (including a rearview camera for power wheelchairs); and (4) OEM engineering/manufacturing partnerships with industry players (e.g., WHILL, Amylior) that provide validation and non-dilutive income. The company’s transition from R&D to commercial scale accelerated after its July 7, 2025 Qualifying Transaction and TSX-V listing, enabling a 16,000 sq. ft. Richmond Hill manufacturing facility (fully live Oct 2025). A major inflection occurred in January 2026 with PDAC verification allowing U.S. Medicare billing for Companion (HCPCS E0986), reducing out-of-pocket barriers and potentially catalyzing dealer adoption across its 300+ authorized dealer channel. Key payers include VA, Medicare/Medicaid, vocational rehab, and workers’ comp, making reimbursement access central to the growth narrative.